This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Phillips, R. M. Articles by Double, J. A. Search for Related Content PubMed PubMed Citation Articles by Phillips, R. M. Articles by Double, J. A.

Angiogenesis in the Hollow Fiber Tumor Model Influences Drug Delivery to Tumor Cells: Implications for Anticancer Drug Screening Programs¹

Clinical Oncology Unit, University of Bradford, Bradford, BD7 1DP, United Kingdom

The National Cancer Institute uses the hollow fiber assay as part of its screening program for anticancer drug discovery. Angiogenesis to hollow fibers implanted s.c. has not been reported, thereby raising concerns about the efficiency of drug delivery and its subsequent effects on chemosensitivity. By extending postimplantation times beyond the 6-day period presently used, extensive vascular networks develop, resulting in both increased delivery and chemosensitivity to doxorubicin. This study suggests that present protocols used to evaluate compounds may produce false negative results, and additional studies to determine the predictive value of the assay are required.

¹ Supported by War on Cancer (Bradford, United Kingdom).

² To whom requests for reprints should be addressed, at Clinical Oncology Unit, University of Bradford, Bradford, BD7 1DP, United Kingdom.

Received 8/24/98. Accepted 10/19/98.

This article has been cited by other articles:

				J. Hasan, S. D. Shnyder, A. R. Clamp, A. T. McGown, R. Bicknell, M. Presta, M. Bibby, J. Double, S. Craig, D. Leeming, et al. Heparin Octasaccharides Inhibit Angiogenesis In vivo Clin. Cancer Res., November 15, 2005; 11(22): 8172 - 8179. [Abstract] [Full Text] [PDF]

				M. G. Hollingshead, J. P. Carter, K. Dougherty, and C. A. Bonomi The Hollow Fiber Assay in Cancer Efficacy Testing in the Developmental Therapeutics Program at the National Cancer Institute Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 351 - 354. [Full Text] [PDF]

				M. Suggitt and M. C. Bibby 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches Clin. Cancer Res., February 1, 2005; 11(3): 971 - 981. [Abstract] [Full Text] [PDF]

				M. Suggitt, D. J. Swaine, G. R. Pettit, and M. C. Bibby Characterization of the Hollow Fiber Assay for the Determination of Microtubule Disruption In vivo Clin. Cancer Res., October 1, 2004; 10(19): 6677 - 6685. [Abstract] [Full Text] [PDF]

				M. D. Sadar, V. A. Akopian, and E. Beraldi Characterization of a New in Vivo Hollow Fiber Model for the Study of Progression of Prostate Cancer to Androgen Independence Mol. Cancer Ther., June 1, 2002; 1(8): 629 - 637. [Abstract] [Full Text] [PDF]

				Q. Mi, B. Cui, G. L. Silva, D. Lantvit, E. Lim, H. Chai, M. You, M. G. Hollingshead, J. G. Mayo, A. D. Kinghorn, et al. Pervilleine A, a Novel Tropane Alkaloid that Reverses the Multidrug-resistance Phenotype Cancer Res., May 1, 2001; 61(10): 4030 - 4037. [Abstract] [Full Text]